Faivre-Finn C, Spigel DR, Senan S, et al. - Given that a significant improvement in progression-free and overall survival (PFS/OS) was seen with durvalumab vs placebo in patients with stage III non-small-cell lung cancer (NSCLC) and stable or responding disease after concurrent, platinum-based chemoradiotherapy (CRT) in the PACIFIC trial, and a range of CT (chemotherapy) and RT (radiotherapy) regimens were used in the trial, researchers report clinical results from PACIFIC according to CRT-related variables in post-hoc, exploratory analyses. Randomization of patients was done 2:1 (1–42 days after CRT) to up to 12 months durvalumab (10 mg/kg intravenously every 2 weeks) or placebo. The baseline variables that were used to define patient subgroups were platinum-based CT (cisplatin/carboplatin); vinorelbine, etoposide, or taxane-based CT (all yes/no); total RT dose (< 60 Gy/60–66 Gy/> 66 Gy); time from last RT dose to randomization (< 14 days/≥ 14 days); and use of pre-CRT induction CT (yes/no). Patient subgroups were assessed for efficacy and safety. Findings demonstrated that prolonged PFS and OS were conferred by durvalumab, regardless of treatment variables associated with previous CRT to which patients with stage III NSCLC had previously stabilized or responded. Robust conclusions are precluded by limited patient numbers as well as imbalances in baseline factors in each subgroup.